Literature DB >> 15852218

The P2 receptors in platelet function.

Béatrice Hechler1, Marco Cattaneo, Christian Gachet.   

Abstract

After vessel wall injury, platelets adhere to the exposed subendothelium, are activated, and release mediators such as thromboxane A (2) (TXA (2)) and nucleotides stored at very high concentration in the so-called dense granules. Among other soluble agents, released nucleotides act in a positive feedback mechanism to cause further platelet activation and amplify platelet responses induced by agents such as thrombin or collagen. Adenine nucleotides act on platelets through three distinct P2 receptors: two are G protein-coupled adenosine diphosphate (ADP) receptors, namely the P2Y (1) and P2Y (12) receptor subtypes; the P2X (1) receptor ligand-gated cation channel is activated by adenosine triphosphate (ATP). The P2Y (1) receptor initiates platelet aggregation but is not sufficient for a full platelet aggregation in response to ADP, whereas the P2Y (12) receptor is responsible for completion of the aggregation to ADP. This receptor, the molecular target of the antithrombotic drug clopidogrel, is responsible for most of the potentiating effects of ADP when platelets are stimulated by agents such as thrombin, collagen, or immune complexes. The P2X (1) receptor is involved in platelet shape change and in activation by collagen under shear conditions. Each of these receptors is coupled to specific signal transduction pathways in response to ADP or ATP and is differentially involved in all of the sequential events involved in platelet function and hemostasis. As such, they represent potential targets for antithrombotic drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15852218     DOI: 10.1055/s-2005-869520

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  30 in total

1.  Enhancement of thrombogenesis by plasma fibronectin cross-linked to fibrin and assembled in platelet thrombi.

Authors:  Jaehyung Cho; Deane F Mosher
Journal:  Blood       Date:  2006-01-03       Impact factor: 22.113

Review 2.  International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.

Authors:  Maria P Abbracchio; Geoffrey Burnstock; Jean-Marie Boeynaems; Eric A Barnard; José L Boyer; Charles Kennedy; Gillian E Knight; Marta Fumagalli; Christian Gachet; Kenneth A Jacobson; Gary A Weisman
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

3.  Inhibition of vascular ectonucleotidase activities by the pro-drugs ticlopidine and clopidogrel favours platelet aggregation.

Authors:  Joanna Lecka; Manjit Singh Rana; Jean Sévigny
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 4.  Interaction of P2 purinergic receptors with cellular macromolecules.

Authors:  Laszlo Köles; Zoltan Gerevich; João Felipe Oliveira; Zoltan Sandor Zadori; Kerstin Wirkner; Peter Illes
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-19       Impact factor: 3.000

5.  P2Y12 or P2Y1 inhibitors reduce platelet deposition in a microfluidic model of thrombosis while apyrase lacks efficacy under flow conditions.

Authors:  S F Maloney; Lawrence F Brass; S L Diamond
Journal:  Integr Biol (Camb)       Date:  2010-01-05       Impact factor: 2.192

6.  The effect of purinergic signaling via the P2Y11 receptor on vascular function in a rat model of acute inflammation.

Authors:  Maria D Dănilă; Andreea Privistirescu; Oana M Duicu; Corina D Rațiu; Denis Angoulvant; Danina M Muntean; Adrian Sturza
Journal:  Mol Cell Biochem       Date:  2017-02-17       Impact factor: 3.396

7.  Aged garlic extract suppresses platelet aggregation by changing the functional property of platelets.

Authors:  Naoaki Morihara; Atsuko Hino
Journal:  J Nat Med       Date:  2016-10-20       Impact factor: 2.343

Review 8.  Inherited platelet disorders: thrombocytopenias and thrombocytopathies.

Authors:  Giovanna D'Andrea; Massimiliano Chetta; Maurizio Margaglione
Journal:  Blood Transfus       Date:  2009-10       Impact factor: 3.443

9.  8-BuS-ATP derivatives as specific NTPDase1 inhibitors.

Authors:  Joanna Lecka; Irina Gillerman; Michel Fausther; Mabrouka Salem; Mercedes N Munkonda; Jean-Philippe Brosseau; Christine Cadot; Mireia Martín-Satué; Pedro d'Orléans-Juste; Eric Rousseau; Donald Poirier; Beat Künzli; Bilha Fischer; Jean Sévigny
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

Review 10.  Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Authors:  Nicholas B Norgard; Mazen Abu-Fadel
Journal:  Vasc Health Risk Manag       Date:  2009-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.